Biodesix, Inc. (BDSX)

0.3716

+0.0238

+(6.84%)

At close: May 9 at 4:00:01 PM EDT

0.3991

+0.03

+(7.40%)

Pre-Market: 7:10:12 AM EDT

Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on Tuesday, May 13. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. An

GlobeNewswire 13 days ago

BDSX
+6.84%
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technologyLOUISVILLE, Colo. and HERCULES, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc (Nasdaq: BDSX), a leading diagnostics solutions company, and Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and diagnostics products, contributed to new research findings from Friends of Cancer Research’s

GlobeNewswire 19 days ago

BIO

BIO-B

BDSX
+6.84%
Biodesix (BDSX) Upgraded to Buy: What Does It Mean for the Stock?

Biodesix (BDSX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 2 months ago

BDSX
+6.84%
Analysts Have Been Trimming Their Biodesix, Inc. (NASDAQ:BDSX) Price Target After Its Latest Report

It's been a good week for Biodesix, Inc. ( NASDAQ:BDSX ) shareholders, because the company has just released its latest...

Simply Wall St. 2 months ago

BDSX
+6.84%
Biodesix Full Year 2024 Earnings: EPS Beats Expectations

Biodesix ( NASDAQ:BDSX ) Full Year 2024 Results Key Financial Results Revenue: US$71.3m (up 45% from FY 2023). Net...

Simply Wall St. 2 months ago

BDSX
+6.84%
Biodesix, Inc. (BDSX): Among Penny Stocks with Insider Buying in 2025

We recently published a list of 12 Penny Stocks with Insider Buying in 2025. In this article, we are going to take a look at where Biodesix, Inc. (NASDAQ:BDSX) stands against other penny stocks with insider buying in 2025. Insider trading can be a reliable signal for gauging the degree of confidence that management has […]

Insider Monkey 2 months ago

BDSX
+6.84%
Biodesix Inc (BDSX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Biodesix Inc (BDSX) reports a 45% revenue increase in 2024, with strategic moves to expand market access and improve profitability in 2025.

GuruFocus.com 2 months ago

BDSX
+6.84%
Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., March 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2024 (fiscal 2024). "Biodesix concluded a stro

GlobeNewswire 2 months ago

BDSX
+6.84%
Biodesix to Present at TD Cowen 45th Annual Health Care Conference

BOULDER, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at TD Cowen 45th Annual Health Care Conference on March 5, 2025. TD Cowen 45th Annual Health Care ConferenceFireside Chat Date: Wednesday, March 5, 2025Fireside Chat Time: 1:50 PM ETLocation: Boston, MA The pr

GlobeNewswire 2 months ago

BDSX
+6.84%
Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

BOULDER, Colo., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2024 after the close of trading on Monday, March 3. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this

GlobeNewswire 2 months ago

BDSX
+6.84%
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

Grew full-year revenue to an estimated $71.3 million, an increase of 45%LOUISVILLE, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter and year ended December 31, 2024 (fiscal 2024). The financial results included in this release pertaining to the fourth quarter and fiscal 2024 are preliminary, unaudited, and subject to final review and adjustment. Preliminary Una

GlobeNewswire 3 months ago

BDSX
+6.84%
BDSX Stock Rises After Publication of Study Data for Nodify CDT Test

Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.

Zacks 3 months ago

BDSX
+6.84%

ABT
Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

Analysis of 447 patients receiving the Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal reaffirms test performanceLOUISVILLE, Colo., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced a new post-market clinical validation study was published in CHEST Pulmonary Journal that reaffirms the previously established performance of the Nodify CDT® blood-based lung nodule test. Clinica

GlobeNewswire 4 months ago

BDSX
+6.84%
Insider Buys Additional US$234k In Biodesix Stock

Potential Biodesix, Inc. ( NASDAQ:BDSX ) shareholders may wish to note that the Independent Director, Jack Schuler...

Simply Wall St. 5 months ago

BDSX
+6.84%
Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Biodesix (BDSX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks 5 months ago

BDSX
+6.84%
Biodesix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Biodesix ( NASDAQ:BDSX ) Third Quarter 2024 Results Key Financial Results Revenue: US$18.2m (up 35% from 3Q 2023). Net...

Simply Wall St. 6 months ago

BDSX
+6.84%
Biodesix Inc (BDSX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...

Biodesix Inc (BDSX) reports a 35% revenue increase, driven by lung diagnostic testing, despite facing weather-related disruptions and rising expenses.

GuruFocus.com 6 months ago

BDSX
+6.84%
Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue Estimates

Biodesix (BDSX) delivered earnings and revenue surprises of 12.50% and 1.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 6 months ago

BDSX
+6.84%
Biodesix Announces Third Quarter 2024 Results and Highlights

Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2024. “The Biodesix team is pleased to report another solid

GlobeNewswire 6 months ago

BDSX
+6.84%
With 47% ownership, Biodesix, Inc. (NASDAQ:BDSX) insiders have a lot riding on the company's future

Key Insights Insiders appear to have a vested interest in Biodesix's growth, as seen by their sizeable ownership The...

Simply Wall St. 6 months ago

BDSX
+6.84%

Performance Overview

Return	BDSX	S&P 500 (^GSPC)
YTD	-75.71%	-3.77%
1-Year	-76.03%	+8.55%
3-Year	-79.80%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TARIFFS LATEST

Biodesix, Inc. (BDSX)

Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Biodesix (BDSX) Upgraded to Buy: What Does It Mean for the Stock?

Analysts Have Been Trimming Their Biodesix, Inc. (NASDAQ:BDSX) Price Target After Its Latest Report

Biodesix Full Year 2024 Earnings: EPS Beats Expectations

Biodesix, Inc. (BDSX): Among Penny Stocks with Insider Buying in 2025

Biodesix Inc (BDSX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

Biodesix to Present at TD Cowen 45th Annual Health Care Conference

Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

BDSX Stock Rises After Publication of Study Data for Nodify CDT Test

Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

Insider Buys Additional US$234k In Biodesix Stock

Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Biodesix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Biodesix Inc (BDSX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...

Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue Estimates

Biodesix Announces Third Quarter 2024 Results and Highlights

With 47% ownership, Biodesix, Inc. (NASDAQ:BDSX) insiders have a lot riding on the company's future

Performance Overview